Positronpharma

Positron Pharma is a leading Brazilian radiopharmaceutical company specializing in the production and distribution of diagnostic imaging agents for Positron Emission Tomography (PET). As a core component of the RPH Group, the company operates a network of cyclotron facilities strategically located across Brazil to provide hospitals and clinics with short-lived radioisotopes. Their product portfolio includes [18F]FDG for metabolic imaging in oncology, as well as advanced tracers such as PSMA for prostate cancer and DOTATATE for neuroendocrine tumors. Positron Pharma manages the entire supply chain, from cyclotron-based isotope production to the automated synthesis and distribution of injectable doses. The company plays a vital role in the South American healthcare landscape by expanding access to high-precision molecular diagnostics for cancer, heart disease, and neurological disorders. Through its commitment to GMP standards and technological innovation, Positron Pharma continues to expand the availability of advanced diagnostic imaging in the region.